Mineralys Therapeutics, Inc. (MLYS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Mineralys Therapeutics, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 25.80 $ — 38% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -23.9%
- ROCE > 15% -26.4%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 135.7% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 657 m net cash passed
- Operating cash flow covers the profits of the last three years 14 m failed
- Return on capital at 15% or higher, or up versus two years ago -26.4% failed
- Insiders hold at least 10% or are net buyers 0.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 89.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.24 | -2.53 – -1.74 | 0 | 2.2% | 8 |
| 12/31/2027 | -2.10 | -3.28 – 1.01 | 121 | 6.4% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.57 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.98 | – | 0 | – | -143,958.80 | -67 | -67 |
| 2025: Q1 | -0.79 | – | 0 | – | – | -46 | -46 |
| 2025: Q2 | -0.66 | – | 0 | – | – | -30 | -30 |
| 2025: Q3 | -0.52 | – | 0 | – | – | -29 | -29 |
| 2025: Q4 | -0.40 | – | 0 | -100.00 | – | -38 | -38 |
| 2026: Q1 | -0.47 | – | 0 | – | – | -40 | -40 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2020 | 0 | -3 | -3 | -0.74 | -2 | -4 | 1 |
| 2021 | 0 | -19 | -19 | -3.89 | -15 | -23 | 11 |
| 2022 | 0 | -31 | -30 | -5.77 | -29 | -52 | 114 |
| 2023 | 0 | -85 | -72 | -1.99 | -81 | 241 | 252 |
| 2024 | 0 | -192 | -178 | -3.66 | -166 | 191 | 206 |
| 2025 | 0 | -171 | -155 | -2.29 | -142 | 647 | 662 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Mineralys Therapeutics, Inc., ein biopharmazeutisches Unternehmen, entwickelt Medikamente gegen Krankheiten, die durch fehlregulierten Aldosteronspiegel verursacht werden, in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 76 |
| Headquarters | Radnor, PA |
| Address | 150 N. Radnor Chester Road, 19087 Radnor, United States |
| Phone | 888 378 6240 |
| Website | mineralystx.com |
| IPO Date | 10. Feb 2023 |
| ISIN | US6031701013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jon Congleton | President, CEO & Director | 1963 |
| Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Director | 1977 |
| Adam Scott Levy | CFO & Secretary | 1978 |
| David M. Rodman M.D. | Chief Medical Officer | 1955 |
| Jeffrey A. Munsie J.D. | Chief Legal Officer | 1977 |
| Robert McKean Ph.D. | Senior Vice President of CMC | – |
| Danielle Mahoney | Senior Vice President of Quality Assurance | – |
| Jessica Ibbitson | Executive Vice President of Operations | – |
| Eric J. Warren R.Ph. | Chief Commercial Officer | 1972 |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 21. Jul 2026 | Warren Eric | Chief Commercial Officer | Sell | 7,438 | 26.87 | 199,885 |
| 21. Jul 2026 | Warren Eric | Chief Commercial Officer | Other | 7,438 | 13.24 | 98,479 |
| 17. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Sell | 416 | 26.53 | 11,036 |
| 17. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Other | 416 | 15.44 | 6,423 |
| 15. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Sell | 6,349 | 26.61 | 168,955 |
| 13. Jul 2026 | Congleton Jon | Chief Executive Officer | Sell | 10,700 | 27.24 | 291,441 |
| 13. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Sell | 14,058 | 27.58 | 387,717 |
| 13. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Other | 6,349 | 1.08 | 6,857 |
| 13. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Other | 4,167 | 14.25 | 59,380 |
| 13. Jul 2026 | Rodman David Malcom | Chief Medical Officer | Other | 3,542 | 10.20 | 36,128 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.